Shree Ganesh Remedies Limited (SGRL) - A pioneer in API intermediaries and Speciality chemicals?

Stock Opportunities Not-so-Hidden Gems
1

About company:

  • Started as a small pharma company in 1992 and later Chandu Kothia, chairman & MD founded Shree Ganesh Remedies in 2004. Company has two decades of experience in the pharmaceutical sector, and is one of the leading manufacturers of Pharmaceutical Intermediates and Fine & Speciality Chemicals in India.

  • Its products find application in multiple industries including pharmaceutical, polymers, agrochemicals, electronics, aroma industry and many others.

  • It’s a family run business as father and both sons are fully involved in the business operations.

Manufacturing facilities:

  • Company has two manufacturing plants in Ankaleshwar, GIDC Gujarat and both of them are located close proximity to each other.

  • They have a total of 10 production blocks (2 of them are upcoming).

  • Unit-1 production area : 3,76,000 sft

  • Unit-2 production area : 36,500 sft

  • In addition to these plants, they also recently acquired the adjoining company with land area of ~2,15,000 sft which is now merged and this will be used for future expansion.

Business segments:

  • Company is mainly into three different verticals:
    • Human health API intermediaries
    • Veterinary API intermediaries
    • Specialty and fine chemicals

  • They have a 40+ product portfolio, 32 in API intermediaries and 11 in specialty chemicals. 4 of their products have more than 50% market share.

  • Clients spread in more than 15 countries. They want to focus on niche chemistries and provide the best possible solutions to their customers.

  • Company also started a subsidiary in the USA to strengthen marketing there.

  • They also entered into contract manufacturing with some of the Europe clients and one of the projects is already producing revenues from last quarter. Currently they have 3 ongoing projects.

Research & Technology:

  • Company believes in Research & Technology is the way to sustainable growth and has recently opened a dedicated facility for R&T. Focus of the R & T team is to develop not only new products but also focus on improving existing processes. In future they want to get into more sub segments of specialty chemicals to attract more clients.

  • More than 50 people are working in research & process development.

  • A new pilot plant has been set up and commenced operations to reduce the overall process and development time. The best practices from here will be shared to commercial sites for faster production, better lead times, and better utilization of the capacity.

  • As you can see there is a 3 fold increase in fume hoods from 2022 to 2023.

  • They are spending around 3-4% of revenue in R & D from the last few years.

Revenues:

  • Revenue:
    • H1FY24 : 60 crores vs H1FY23 39 crores
  • EBITDA
    • H1FY24: 17.5 crores(29%) vs H1FY23: 11 crores(28%)
  • Net profit:
    • H1FY24: 11.3 crores vs H1FY23 6.8 crores.

  • Company has been able to increase revenues consistently over the years.

Revenue distribution:

  • API intermediaries vs specialty chemicals: 59.3% vs 40.7% (FY23)
  • Exports vs Domestic: 68.5% vs 31.5% (FY23)

Capex:

  • Company has spent more than 40 crores in FY23 for acquiring the land adjacent to unit-1, setting up a new R & T block & pilot plant etc. This is by far the highest capex spent in the history of the company. Company expects to spend 15 crores for FY24.

Clients:

  • Some of their marquee client list includes:

Management:

  • Mr. Chandu Kothia who is the chairman & MD of the company has more than 30 years of industry experience. He started Ashoka pharma in early 90s and later in 2004 started Shree Ganesh Remedies to cater to international clients and to expand business further. HIs educational background is in chemistry and he started involving both of his sons into business. Both of them also pursued masters in chemicals.

  • Gunjan Kothia thinks that the company has just started talked about the future prospects in the FY23 annual report (taken as is):

  1. We are setting up a new GMP manufacturing block designed to cater to advanced API Intermediates, reinforcing our commitment to delivering high quality pharmaceutical solutions to our valued customers. This world-class facility is built in with the flexibility to manufacture in-house APIs which is further under strategic evaluation. We expect this facility to commence operations in the second half of FY24.

  2. We have invested in an advanced manufacturing block dedicated to high-pressure reactions enhancing our pressure handling capacity up to 600 psi. This facility will allow us to widen our product range to better cater to our customers, amplifying our business horizon appreciably. With the commissioning of this facility, we will be one of the few players in our business space, with this capability placing us in a niche position in our business space.

  3. We are setting up a cutting-edge Pilot Block, which will facilitate scaling up complex processes and optimization for the manufacturing processes. In addition, it will also serve as a commercial manufacturing block for small volume high-value products. When commissioned, the unit will provide the much-needed capacity and flexibility in our infrastructure to cater to high-value products. The unit should be operational in Q2 FY-24.

  4. We have set up a new R&D block that houses the latest equipment and cutting-edge technology, allowing us to conduct advanced research and deliver complex, high-quality products. This investment is testimony of our commitment to fostering innovation and supporting the Pharma and Specialty Chemicals manufacturers in the US and the EU to reduce their dependence on China.

Shareholding:

  • Promoters currently holding about 69.33% and total number of shareholders are also at about 7730 (relatively new listed company, came to main board in 2020).

Coverage:

What I have not covered in this:

  • I haven’t gone through their chemistry processes and technologies, the company website has listed them. I am into computer science engineering and don’t have much understanding of organic chemistry.

  • I haven’t talked much on risks, I definitely feel there is a risk in raw materials procurement. It will be great if someone highlights the risks of the company.

  • I haven’t done a deep dive into financials, I would like to do it as and when I understand more about business.

  • I haven’t talked much on the management outlook and opportunities for the company, FY23 annual report covers this and I can update in the coming days about the same.

  • Scuttlebutt from EPFO website to get a feeling of salaries and increments, number of employee etc. I will be doing that in coming days.

References:

Disclosure:

  • After being a passive observer for several years I started being active in the forum again and started writing recently on this forum. This is my first post on the stock idea and would like to build upon the initial post by discussing with other folks and ready to learn from other people in the forum.

  • Started buying after Q2 results and will continue to buy in the upcoming days as business evolves and I get more confidence in the business.

42 Likes
3

Happy new year 2024, everyone.

Scuttlebutt from EPFO website to get a feeling of salaries and increments, number of employee etc. I will be doing that in coming days.

I did some analysis of the number of employee data reported to EPFO. Company has been recruiting people continuously and currently have 121 employee as of Nov 23.

image
image1060×450 62.8 KB

They are consistently adding more than 20% workforce every year except for last couple of years where the growth is >15%. Though we still have 4 months left in 2023/24. There is a sudden dip in Dec-18 causing a substantial reduction in number of employee and they are back to Mar-18 numbers in Mar-20.

image
image750×450 54 KB

Interestingly revenue per employee peaked in Mar-20 (~1cr) and again started rising after Covid dip, they are still behind the Mar-20 peak. Profit per employee is consistently around 16 lakhs. New business orders in coming quarters should help increase these numbers (operating leverage kicking in), as long as company is hiring workforce this should be a good sign that company is in expansion phase and trying to become a pioneer in the field they are operating in.

image
image750×450 42.1 KB

14 Likes
4

SGRL posted a mixed set of Q3 FY24 results.

Q3 FY24 Q3 FY23 YOY Q2 FY24 QOQ 9M FY24 9M FY23 YOY
Revenue 27.97 21.99 27.19% 33.42 -16.31% 88.11 60.89 44.70%
EBITDA 9.32 6.79 37.26% 10.03 -7.08% 26.86 17.77 51.15%
EBITDA % 33.32% 30.88% 7.91% 30.01% 11.03% 30.48% 29.18% 4.46%
PAT 4.8 4.35 10.34% 6.55 -26.72% 16.12 11.15 44.57%
PAT % 17.16% 19.78% -13.25% 19.60% -12.44% 18.30% 18.31% -0.09%

Financial Highlights

  • Company posted a robust 27% yoy increase in revenue, with 37.26% increase in EBITDA and 244bps in EBIDTA margins as well (at 33.32%).
  • Tax rate was 35% (against ~24% qoq/yoy) causing a dent in the PAT (down 13% yoy).
  • On a qoq basis company posted de-growth of 16% in revenues and 27% in PAT.
  • While Specialty chemicals posted robust growth, there is a significant de-growth in API intermediaries revenue and export revenues. The increase in margins attributed to the one of CAMS projects being commercialized.
    image
    image918×689 148 KB

Business updates

image
image878×199 24.7 KB

References:

5 Likes
5

I have also been following the company for sometime. SGRL looks like a very differentiated pharma company operating in the intermediates space where there are lots of growth opportunities. I feel they are following the path taken by Ami Organics, and market really likes these kind of business models (high margins, working capital investment, high ROICs, leadership in core products). I am sharing my notes from their last couple of AGMs.

AGM22 notes

  • Europe gas supply problems: 10-20% of business has been converted from Euro to USD
  • Currency: Got 2mn in Euro in FY22. About 60% of business was in USD and planning to increase it to 65-70% in FY23
  • GMP plant: validation will be finished by March and benefit will flow in nos in FY24 (played out)
  • Growth: Expect 20-25% growth on sales (growth was 26%)
  • Current capacity utilization is 74-75%. Focusing on improving product mix to improve value rather than just focus on volumes (played out)
  • Specialty chemicals:40% of revenues, pharma intermediates: 60% of revenues
  • Jaiswal Pharmachem: Getting legal approvals for transfer of plots, will then refurbish plant and machinery
  • Capability to handle multiple step synthesis, face less competition in few products because it’s a long process to get approval from API manufacturers and they are mentioned in the API cos’ DMF filings, which is hard to change afterwards
  • Customers (US/European) have been for last 10-15 years because of product quality
  • For some products have got very high market shares because they develop 8-10 step synthesis process and work from basic raw materials which are developed from scratch and procured indigenously
  • Thionyl chloride: Transpek is not a competitor. Contributes 40-50% of revenues
  • API and advanced intermediate manufacturing in GMP plant will manufacture higher realization products and increase margins
  • Want to get into exclusive contract manufacturing with EU/American customers for providing stability of revenues

AGM23 notes

- In our annual report, we talk very bullishly about setting up a much larger platform in the future. Can you talk about management ambitions about growth and what do we mean by unlocking something much bigger in the future?
- In our current business, what is the end market of the intermediates that we are supplying to our customers? Are the final APIs or formulations getting sold to regulated markets of US/Europe/Japan or are they largely going to unregulated markets? Can you give a split between the two?

Are not into API manufacturing, already on DMFs of many API manufacturers (domestic + European)
KSM supplier name has to be mentioned in DMF

- With commissioning of our GMP plant, how long will it take for us to get into DMFs/CEPs of API suppliers so that we can sell intermediates for regulated markets? How easy is it for our customer to add a new supplier in regulated markets?
- With our own GMP plant, do we also plan to enter into API manufacturing?
No plans of entering API. Will only enter APIs where they already produce KSM and intermediates and are thus cost competitive

- In the recent presentation, we talked about 3 CRAMS projects. What is the potential of these and what kind of scalability can we see in these projects?

CRAMS projects

  • 2 projects from existing customers, 1 project from a new customer
  • In 1 project, process is patented by clients, final product approval is ongoing in market (new patented molecules), expect small volume in FY24 and peak in FY25/26. 2 suppliers: SGRL and 1 Chinese competitor
  • Even 2nd supplier gets 30% volumes in case of European/American customer
  • In 1 project, SGRL were already manufacturing RM for this product which gave them advantage to get this project
  • Getting contracts from multiple customers for low volume specialty molecules ($400-1000/kg)
  • Personal care project: Brought by one European agent; have added a new technology. No other supplier from India or China
  • Third project (agro space): Customer was manufacturing in their European facility at small scale (process patented by customer). Customer had reached out to all potential manufacturers, and SGRL was quick to grab this opportunity. 1 other supplier in China
  • Expect bare minimum peak revenues of 30-50 cr. (assuming 50% of expected demand)
  • For 2 CRAM projects, will be using high pressure block and won’t require additional capex
  • 1 project will use flow technology

- What is our current reactor capacity and what utilization are we operating at?
Reactor capacity does not determine revenue generation as product mix. 230kl capacity, plan to add 80-100 kl capacity every year. FY23: 80-82% utilization. Batch manufacturing process
Expect 2-2.5x fixed asset turns from incremental expansion

- With us commissioning high pressure reactions block, what kind of traction are we seeing? How differentiated is this technology and who are the other companies doing this in India?
- What products are we making in carbon-carbon coupling chemistry under CDMO model? What’s the end usage of these products?
Goes into specialty and pharma space, customers are in USA and Europe. Products are expensive and chemistry is niche

- With recent genericization of gliptins, have we got into DMF/CEPs of API suppliers for these molecules?
- How much sales comes from our top 3 and top 5 customers?
Top 3: 60%, Top 5: 70%

- How much sales comes from our top 3 and top 5 products? What are those products and what is their end usage?
Top 5: 40-45% of revenues

- At our last AGM, we had mentioned something about thionyl fluoride. Do we have fluorination capabilities and can you talk more about it?
Do not manufacture thionyl fluoride, only thionyl chloride. Chlorination and bromination are their specialty

- How much progress have we made in building our new plant in Jaiswal Pharmachem? What is the proposed timeline for expansion and how much capacity do we plan to install here?
Business breakup

  • Exports: 68%, domestic: 32%
  • FY23: 30% volume growth (Rs. 1200-1300/kg average realizations)
  • Pharma: 60%, 40% specialty and fine chemicals (20-25% of the 40% is to agchem and other is in niche polymer and electronic chemical space)
  • Fine and specialty products should contribute towards future growth, specially from CRAMS business
  • Will maintain same growth in FY24 as seen in last couple of years

Capex:

  • FY23: 42 cr. (30 cr. for Jaiswal acquisition + enhance R&D + production capabilities)
  • Expect 15 cr. capex for capacity expansion in FY24. Building up a warehouse in Jaiswal unit
  • Incurring heavy capex in new technologies to optimize production levels rather than just to enhance capacity (increased annual capacity from 700-800 tons to 1200-1300 tons from same line)
  • Will first utilize Jaiswal unit by 50-60% before moving to Dahej
  • Since last 3-4 years, they have been investing to develop their core chemistry. Very few cos practice this range of chemistry at SGRL’s scale
  • New R&D unit has been commissioned in Jaiswal

3 different land parcels

  • Unit 1 (Ankleshwar): 10,000 sq.m; has increased to 35,000 sq.m with acquisition of Jaiswal Pharmachem; High pressure block is a standalone building; Pilot plant is another standalone building. Has total 7 blocks
  • Unit 2 (Ankleshwar; 1.5km away from Unit): 3,000 sq.m. 2 buildings which are considered as 1 block
  • Dahej: 40,000 sq.m; EC and NOC granted; Got opportunity to acquire adjoining land Jaiswal Pharmachem land and prefe
  • 8 blocks: added GMP block to advance portfolio in more advanced pharma intermediate space (in Unit 1); Current product mix is KSM or basic intermediate
  • Pilot plants are used for products with volumes <1000 kg/year

Miscellaneous

  • Divis: largely into pharma intermediates and APIs vs SGRL is largely into intermediates. SGRL is more diversified into fine and specialty chemical vs Divis largely focusing on pharma
  • Took advantage and acquired RMs at cheaper price due to recent Chinese dumping
  • Key competitors will be cos manufacturing pharma intermediates (one comparable co is Ami Organics)
  • Low Chinese dependence, good backward integration (atleast 4-5 steps), comfortable with the technology and chemistry
  • Leading global producer of 2 products
  • Were able to maintain margins – higher scales due to volume growth drove efficiency, better RM procurement

Disclosure: Invested (position size here, participated through rights subscription in last-30 days)

29 Likes
6

Hi Harsh, Thank you for your notes. Can you pls guide - where can I find the transcript of the AGMs.

1 Like
7

I recently found that SGRL’s Director, Mr. Gunjan Chandulal Kothia, holds a directorship in a company called Bioshield Ag. I’m interested in understanding if SGRL has any stake in Bioshield Ag, or if Mr. Gunjan’s association is solely on a personal level. I’m wondering if anyone in this forum has any info on this matter. I’ve reached out to SGRL’s investor relations but have yet to receive a response. For reference, please see the following links: Reference: 1) https://www.bioshieldag.com/ 2) Bioshield Ag Ltd - Company Profile - Endole

1 Like
8

Is there any AGM notes for FY24 released yet ?

1 Like
9

Steep 15% drop in stock price today. Management needs to do a concall to explain the 7.2% drop in revenue and future guidance

2 Likes
10
1 Like
11

image
image1968×1500 370 KB

11 Likes
13

Quick highlights of first detailed presentation by the Company:
fb8f6228-4032-48c5-bca4-11aa4e99ca06.pdf (4.4 MB)

  • Higher margin biz (Specialty chemicals) to contribute >60% in future (currently it seems 40%)
  • In Specialty
    chemicals:
    a. Evolved from 20-50 tonnes/year to 80-100 tonnes/year, now
    receiving inquiries for > 500 tonnes per year
    b. At inflextion point, scaling up with global giants
  • 40 team of R&D: 20 PHDs
  • Marquee client: BASF, Laurus, Aarti, Dipharma, Lonza, Cipla
  • Land parcel available for future expansion
  • Block 8 is operational since Q1 FY’25, to contribute meaningfully in Q3 FY’25
  • Block 7 to be completed in 18 months (Dec’25): production of complex, niche specialty chemicals using automated plants, targeting low volume, high-profitability molecules
  • They focus on products requiring 3-4 different chemistries rather than just 3-4 reaction steps reducing competition
  • enter into product which fits their margin profile
  • Sustainable EBIDTA: 24 to 28%; last two quarters higher EBIDTA due to RM pricing
15 Likes
14

Revocation of Closure order by GPCB

2 Likes
15

AR24 notes

Financials:

  • FOB Exports: 63.1 cr. (vs 61.86 cr. in FY23)
  • Domestic sales: 62.81 cr. (vs 28.36 cr. in FY23)
  • Foreign exchange outgo: 15.72 cr. (vs 21.35 cr. in FY23)
  • Issued 8,30,893 equity shares under rights issue (7.48 cr. under final call)
  • Inventory writedown: 1.73 cr.
  • Product sales: 124.8 cr. (vs 90.22 cr. in FY23)
  • No new promoter loans received

Product basket

  • Pharmaceutical intermediates : 32+ products; 70.38 cr. (vs 53.59 cr. in FY23)

    • Human : Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic

    • Veterinary : Feed Additives, Antiparasitic, Anti-Inflammator

  • Fine and Specialty Chemicals : 11+ products; 55.52 cr. (vs 36.64 cr. in FY23)

    • Aroma & Health, Agrochem, Polymer, Electronics

Capex

  • Restatements have happened affecting previous year capexes
  • Fixed asset addition: 27.54 cr. (mostly in buildings + plant & machinery)
  • CWIP: 16.63 cr. (vs 41.77 cr. in FY23)
  • PPE: 42.91 cr. (vs 34.68 cr. in FY23); cashflow from investing statement shows 31.14 cr. of capex vs 49.14 cr. in FY23
  • Invested 27.54 cr. (vs 38.6 cr. in FY23) in new infrastructure
  • Investing in 2MW solar power project in Gujarat

Manufacturing facilities

  • 40,000 sqm total area (vs 36,500 sqm in FY23)

  • 35 (vs 25 in FY23) glass line reactors, 28 (vs 23 in FY23) stainless steel reactors

  • 18 fume hoods (same in FY23)

  • 10 reaction technologies (same in FY23)

  • 12 reactors for pilot plant (same in FY23)

General:

  • New scale up facilities and GMP plants are key growth drives for next years

  • Their existing presence in the electronics specialty chemicals market positions them perfectly to capitalize on the government’s push for domestic semiconductor manufacturing

  • 100+ customers spread over 17 countries

  • Solidifying position as a leading building block chemical manufacturer and as a CDMO, expanded research and production capabilities

  • Commissioned all new manufacturing blocks in the recently acquired plant, new manufacturing block saves upto 15% more energy

  • 2 subsidiaries: Kamalam Foundation (a Section 8 Company) and SGRL USA Inc (invested 8.3 lakhs)

  • 4 products with 50%+ market share

  • Employees : 139 (vs 110 in FY23)

  • Salaries of employees other than KMP increased by 26.35% (vs 17.53% in FY23) and for KMP increased by 32.31% (vs 9.55% in FY23)

  • Disputed taxes : 4.97 cr. (vs 4.17 cr. in FY23)

  • Share price : 245.5 (low), 736 (high)

  • Shareholders : 6814 (same as FY23)

  • Promoter shareholding : 69.33% (vs 69.34% in FY23)

  • Bankers : DBS, Kotak. DBS Bank loan is repayable in 66 EMIs, carries interest rate of 3.40%. Kotak loan is repayable in 66 EMIs, carries interest rate of 3month Euribor + bank spread

R&D:

  • 2.54 cr. (vs 2.08 cr. in FY23)
  • Established a cutting-edge Research Center and a dedicated Pilot Plant
  • Technologies: Liquid-Gas Reaction (new), High-Pressure Reaction, Cryogenic Reaction, Photo-Catalytic Reaction (new), Thin-film Distillation (new), High Fraction Distillation (new)
  • Chemistries: Chlorination using HCL or Chlorine Gas, Photo-Chlorination & Bromination, Reduction using Hydride (new), DIBAL and H2 Gas (new), Friedel Crafts & Grignard, Sonagashira and Suzuki Coupling (new), Chiral Resolution

Disclosure: Invested (no transactions in last-30 days)

18 Likes
17

Sharing AGM notes

General

  • 24-28% sustainable EBITDA margins
  • New block – multipurpose – high value low volume
  • New R&D building in Ankleshwar (kilo block). Increasing their R&D strength. R&D ~ 2% of sales and want to increase to 3-4% (want to do more projects in fine and petchem space)
  • R&D head has 14-year experience (ex-Unichem, Amnil pharma). With SGRL since 4-5 years
  • Not in bulk chemistry so far (no product where they are manufacturing 100-200 tons)
  • Want to maintain growth they have been seeing in last 3-4 years
  • CRAMS project didn’t contribute in Q1FY25 resulting in revenue dip, CRAMS is always lumpy (may see supplies every 2 years)
  • Ankleshwar will cater to customer synthesis / multipurpose blocks
  • Dahej: larger scale products and will be driven by customers
  • 40500 sq meters acquired for future expansion

Electronics chemical: discussing with potential customers (NDA) in Europe. In few projects, they are in last phase of R&D and expect commercialization in 2-3 years
Since 2004, their focus was on API intermediates in the pharma sector. Since last 5-years, they have started catering to fine and specialty chemicals and focusing on respective chemistries. Multipurpose blocks help them manufacture molecules in any given chemistry. Expect product mix to change towards fine and specialty chemicals from pharma side. Make similar margins in specialty chemical and pharma

- In our current business, what is the mix of regulated vs unregulated markets that our end products are sold into?

Not into APIs, only present in unregulated markets and generic products. They cater to innovators and have large market shares in 2-3 products

- With the recent commercialization of our GMP plant, what kind of opportunities are we seeing? Are we going more into regulated market supply? What does our product pipeline look like?

Advanced intermediates for European customers – only few products using 1 GMP block. Running GMP block is expensive, and they only do it if the product can justify

- Can you briefly update us about the 3 CRAMS projects we had announced in FY23. How are these scaling up and what kind of revenues can we see in next 2-3 years from these products?

1st project – Q4 contribution (fine chemicals).
Cosmetic – project has been dropped
Agrochemicals – submitted small quantities from pilot plant (to be commercialized in 18-20 months)

- Have we won new CRAMS contracts? Can you provide us an update of latest business developments?

Getting more enquiries – haven’t seen any agreements yet

- What kind of product realizations do we expect in next few years? We were mentioning about new products of $500-1000/kg realizations, are we on track to launch more of these?

800 tons – earlier products were 500-1500/kg. New products are 3000-4000/kg

- What is our current reactor capacity and what utilization are we operating at? When do we go for next phase of expansion or is peak capex behind us?

After Plant 8 capacity has increased to 350 kl (from 230 kl) – prior utilization: 80-85% (full realization). Plant 8 utilization will require 18-24 months
Plant 7 is being designed – 20-24 months
Can do 2 more plants (Plants 9 and 10)

- Given that we have significant land in Dahej, any plans on a greenfield capex?

Bulk projects – customer dedicated. In discussion with 2 customers, agreements still to be signed

- How much sales comes from our top 3 and top 5 products? What are those products and what is their end usage?

5 products – 60-62% of sales (reduced from 80% earlier)

Disclosure: Invested (no transactions in last-30 days)

20 Likes
18

The only concern i have is on the KMP salaries (for Kundan & Parth) & Related Party Transitions. (as the DRHP says promoter has other companies in the same business - need a deeper dive)

Positives -

  1. Strong growth numbers from sales and profitability perspective.
  2. High Capex in progress
  3. Promoter shareholding ~70%
  4. Management succession in place (Kundan & Parth)
  5. Increased revenue contribution from Fine & Specialty Chemicals
  6. R&D expenses - ~5%

Negatives -

  1. Low cash generation 70% when compared with PAT - last 9 years
  2. Capex expenses are not met. Negative FCF & increase in debt (last 2 years)
  3. Promoter salary increasing disproportinaletluy ( for Kundan & Parth)
  4. Need to do deeper dive in Related party transactions
  5. Regular Equity dilution

Started a tracking position.

2 Likes
19

First ever Concall on 8th November:

8 Likes
20

Audio recording of Q2 Concall:

5 Likes
21

Shree Ganesh Remedies Limited (SGRL) Q2 FY25 Earnings Concall

Current Financial Performance:

  • Despite a challenging operating environment, SGRL had a strong Q2 FY25.
  • Revenue from operations was ₹32.33 crores, a 3% decrease YoY.
  • EBITDA was ₹11.31 crores, a 23% increase YoY.
  • Profit after tax was ₹6.39 crores, a 2% decrease YoY.
  • EBITDA margin was 35%, a significant 737 basis point increase YoY.

Margins:

  • The improved margin is primarily attributed to the commercialisation of one of their CRAMS projects and the timely buying of raw materials.
  • The high margin is also due to the high value of the CRAMS project, although price pressure is expected as volumes increase.
  • SGRL aims to maintain healthy margins through backward integration by manufacturing key raw materials in-house.
  • Management believes a sustainable EBITDA margin range of 24-28% is achievable in the long term, as lower margins from other products will offset the higher margins from CRAMS projects over 3-5 years.

Growth Plans for the Future:

  • SGRL’s future growth strategy is focused on optimising their product mix and enhancing profitability through innovative approaches.
  • They are also focused on shifting from being a third supplier to a second supplier for larger-scale projects.
  • They plan to establish a regular practice of half-yearly conference calls to enhance transparency and foster stronger relationships with stakeholders.
  • strategically shifting towards the specialty and fine chemicals, particularly for the patented molecules that require a strong technical know-how

Future Guidance:

  • SGRL expects revenue to remain largely flat in FY25 due to dampening demand from the European region.
  • They anticipate significant growth in the future as new CRAMS projects ramp up.
  • Guidance is for a 24-28% EBITDA margin range in the next 3-5 years.

Capacity Expansion:

  • SGRL is expanding its capacity at both its Ankleshwar and Dahej sites.
  • At Ankleshwar, they have acquired an adjoining property and are finalising the design for Block 7.
  • Block 8 commenced commercial operation in Q1 FY25.
  • The Dahej site will facilitate large-scale projects requiring dedicated plant setups with major corporates.
  • Management is confident in their ability to meet future demand and ramp production through capacity expansion and technology improvements.
  • At Ankleshwar, we acquired an adjoining property of 20,100 square meters in 2002, which supports ongoing expansion in pharmaceutical intermediates, speciality chemicals and fine chemicals. At our Dahej side, we also have a land parcel of 40,554 square meters for future expansion.
  • Block 8 is anticipated to make a meaningful contribution in the coming quarters.

New Products:

  • SGRL is exploring opportunities to expand into dedicated blocks for oxidation and low-temperature chemistry.
  • They also focus on developing new complex molecules and enhancing advanced manufacturing capabilities.
  • SGRL has commercialized one CRAMS project and has 3-4 more in the pipeline.
  • These projects are in the agrochemicals, fine and speciality chemicals, and electronic chemical spaces, with customers from Europe, Japan, and the USA.
    Demand Scenario:
  • Demand from the European region, SGRL’s major market, has been dampening, leading to suppressed revenue growth.
  • However, they see increased inquiries in the fine and speciality chemical space through exhibitions.
  • Management believes demand for CRAMS projects will increase in the future.

New Initiatives:

  • SGRL is shifting its focus from pharmaceutical intermediates for off-patent and generic drugs to speciality and fine chemicals, particularly for patented molecules.
  • They aim to transition from a third supplier for medium-sized projects to a second supplier for larger-scale projects.

Risks Associated with the Business:

  • Dependence on the European market: The company’s significant reliance on the European region exposes it to risks associated with economic downturns and regulatory changes.
  • Price pressure on CRAMS projects: As the volume of CRAMS projects increases, SGRL may face pressure to reduce prices, which could impact margins.
  • Long lead times for CRAMS projects: The development and commercialisation of CRAMS projects can take several years, leading to revenue and profit recognition being spread out over a longer period.
6 Likes